[1] Cesareo R, Naciu AM, Iozzino M, et al.  Nodule size as predictive factor of efficacy of radiofrequency ablation in treating autonomously functioning thyroid nodules[J]. Int J Hyperthermia, 2018, 34(5): 617-623.   doi: 10.1080/02656736.2018.1430868
[2] Plummer HS.  The clinical and pathologic relationships of hyperplastic and nonhyperplastic goiter[J]. JAMA, 1913, 61(9): 650-651.   doi: 10.1001/jama.1913.04350090018006
[3] Goetsch E.  Newer methods in the diagnosis of thyroid disorders: pathological and clinical[J]. NY State J Med, 1918, 18: 259-.
[4] Floor SL, Trésallet C, Hébrant A, et al.  microRNA expression in autonomous thyroid adenomas: correlation with mRNA regulation[J]. Mol Cell Endocrinol, 2015, 411: 1-10.   doi: 10.1016/j.mce.2015.04.001
[5] Yan Z, Yangyanqiu W, Shuwen H, et al.  Downregulation of Rap1GAP expression activates the TGF-β/Smad3 pathway to inhibit the expression of sodium/iodine transporter in papillary thyroid carcinoma cells[J]. Biomed Res Int, 2021, 2021: 6840642-.   doi: 10.1155/2021/6840642
[6] Mariani G, Tonacchera M, Grosso M, et al.  The role of nuclear medicine in the clinical management of benign thyroid disorders, part 1: hyperthyroidism[J]. J Nucl Med, 2021, 62(3): 304-312.   doi: 10.2967/jnumed.120.243170
[7] Iemura R, Kirino S, Sutani A, et al.  Autonomously functioning thyroid nodule due to a somatic TSHR mutation[J]. Pediatr Int, 2022, 64(1): e15157-.   doi: 10.1111/PED.15157
[8] Agretti P, De Marco G, Ferrarini E, et al.  Gene expression profile in functioning and non-functioning nodules of autonomous multinodular goiter from an area of iodine deficiency: unexpected common characteristics between the two entities[J]. J Endocrinol Invest, 2022, 45(2): 399-411.   doi: 10.1007/s40618-021-01660-y
[9] Krohn K, Führer D, Bayer Y, et al.  Molecular pathogenesis of euthyroid and toxic multinodular goiter[J]. Endocr Rev, 2005, 26(4): 504-524.   doi: 10.1210/er.2004-0005
[10] McDermott MT.  Hyperthyroidism[J]. Ann Intern Med, 2020, 172(7): ITC49-ITC64.   doi: 10.7326/AITC202004070
[11] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[12] 李晓曦.  实验室检查在甲状腺结节诊治中的合理选择与评价[J]. 中国实用外科杂志, 2015, 35(6): 629-633.   doi: 10.7504/CJPS.ISSN1005-2208.2015.06.11
Li XX.  Rational option and evaluation of laboratory tests for the diagnosis and management of thyroid nodules[J]. Chin J Pract Surg, 2015, 35(6): 629-633.   doi: 10.7504/CJPS.ISSN1005-2208.2015.06.11
[13] 刘雪辉, 李洪均, 于泓煦, 等.  131I治疗自主功能性甲状腺结节临床分析[J]. 重庆医学, 2021, 50(1): 109-112, 117.   doi: 10.3969/j.issn.1671-8348.2021.01.025
Liu XH, Li HJ, Yu HX, et al.  Clinical analysis of 131I treatment for autonomously functioning thyroid nodules[J]. Chongqing Med, 2021, 50(1): 109-112, 117.   doi: 10.3969/j.issn.1671-8348.2021.01.025
[14] 余林英.  彩色多普勒超声鉴别诊断结节性甲状腺肿与甲状腺腺瘤临床价值[J]. 实用中西医结合临床, 2022, 22(11): 84-86, 124.   doi: 10.13638/j.issn.1671-4040.2022.11.025
Yu LY.  Clinical value of color Doppler ultrasound differential diagnosis of nodular goiter and thyroid adenoma[J]. Pract Clin J Integr Tradit Chin West Med, 2022, 22(11): 84-86, 124.   doi: 10.13638/j.issn.1671-4040.2022.11.025
[15] Alexander LF, Patel NJ, Caserta MP, et al.  Thyroid ultrasound: diffuse and nodular disease[J]. Radiol Clin North Am, 2020, 58(6): 1041-1057.   doi: 10.1016/j.rcl.2020.07.003
[16] Giovanella L, Avram AM, Iakovou I, et al.  EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy[J]. Eur J Nucl Med Mol Imaging, 2019, 46(12): 2514-2525.   doi: 10.1007/s00259-019-04472-8
[17] Wong R, Farrell SG, Grossmann M.  Thyroid nodules: diagnosis and management[J]. Med J Aust, 2018, 209(2): 92-98.   doi: 10.5694/mja17.01204
[18] Azevedo MF, Casulari LA.  Hyperfunctioning thyroid cancer: a five-year follow-up[J]. Arq Bras Endocrinol Metabol, 2010, 54(1): 78-80.   doi: 10.1590/s0004-27302010000100013
[19] 刘雪辉, 高志民.  自主功能性甲状腺结节的临床诊疗进展[J]. 国际放射医学核医学杂志, 2020, 44(12): 780-785.   doi: 10.3760/cma.j.cn121381-201910002-00108
Liu XH, Gao ZM.  Progress in the clinical diagnosis and treatment of autonomously functioning thyroid nodule[J]. Int J Radiat Med Nucl Med, 2020, 44(12): 780-785.   doi: 10.3760/cma.j.cn121381-201910002-00108
[20] Gharib H, Papini E, Garber JR, et al.  American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules−2016 update[J]. Endocr Pract, 2016, 22(Suppl 1): S1-60.   doi: 10.4158/EP161208.GL
[21] Papini E, Monpeyssen H, Frasoldati A, et al.  2020 European Thyroid Association clinical practice guideline for the use of image-guided ablation in benign thyroid nodules[J]. Eur Thyroid J, 2020, 9(4): 172-185.   doi: 10.1159/000508484
[22] Vija Racaru L, Grunenwald S, Hindie E, et al.  Management of adenomas and toxic multinodular goiters with Iodine 131[J]. Méd Nucl, 2020, 44(4): 272-276.   doi: 10.1016/j.mednuc.2020.09.001
[23] Mitchell AL, Gandhi A, Scott-Coombes D, et al.  Management of thyroid cancer: United Kingdom national multidisciplinary guidelines[J]. J Laryngol Otol, 2016, 130(Suppl 2): S150-160.   doi: 10.1017/s0022215116000578
[24] Bahn RS, Burch HB, Cooper DS, et al.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J]. Thyroid, 2011, 21(6): 593-646.   doi: 10.1089/thy.2010.0417
[25] Papini E, Pacella CM, Solbiati LA, et al.  Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group[J]. Int J Hyperthermia, 2019, 36(1): 376-382.   doi: 10.1080/02656736.2019.1575482
[26] Matos LPL, Penha RCC, Cardoso-Weide LC, et al.  Regulation of thyroid sodium-iodide symporter in different stages of goiter: possible involvement of reactive oxygen species[J]. Clin Exp Pharmacol Physiol, 2018, 45(4): 326-334.   doi: 10.1111/1440-1681.12887
[27] Vigone MC, Peroni E, Di Frenna M, et al.  "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients[J]. J Endocrinol Invest, 2020, 43(5): 595-600.   doi: 10.1007/s40618-019-01144-0
[28] Ross DS.  Radioiodine therapy for hyperthyroidism[J]. N Engl J Med, 2011, 364(6): 542-550.   doi: 10.1056/NEJMct1007101
[29] Kahraman D, Keller C, Schneider C, et al.  Development of hypothyroidism during long-term follow-up of patients with toxic nodular goitre after radioiodine therapy[J]. Clin Endocrinol, 2012, 76(2): 297-303.   doi: 10.1111/j.1365-2265.2011.04204.x
[30] Roque C, Santos FS, Pilli T, et al.  Long-term effects of radioiodine in toxic multinodular goiter: thyroid volume, function, and autoimmunity[J]. J Clin Endocrinol Metab, 2020, 105(7): e2464-e2470.   doi: 10.1210/clinem/dgaa214
[31] Ronga G, Filesi M, D'Apollo R, et al.  Autonomous functioning thyroid nodules and 131I in diagnosis and therapy after 50 years of experience: what is still open to debate?[J]. Clin Nucl Med, 2013, 38(5): 349-353.   doi: 10.1097/RLU.0b013e318286bbda
[32] Dekker BL, Links MH, Kobold ACM, et al.  Low iodine diet of four days is sufficient preparation for 131I therapy in differentiated thyroid cancer patients[J]. J Clin Endocrinol Metab, 2021, 107(2): e604-e611.   doi: 10.1210/clinem/dgab691
[33] Manna D, Roy G, Mugesh G.  Antithyroid drugs and their analogues: synthesis, structure, and mechanism of action[J]. Acc Chem Res, 2013, 46(11): 2706-2715.   doi: 10.1021/ar4001229
[34] Demir BK, Karakilic E, Saygili ES, et al.  Predictors of hypothyroidism following empirical dose radioiodine in toxic thyroid nodules: real-life experience[J]. Endocr Pract, 2022, 28(8): 749-753.   doi: 10.1016/j.eprac.2022.05.001
[35] Bonnema SJ, Hegedüs L.  Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome[J]. Endocr Rev, 2012, 33(6): 920-980.   doi: 10.1210/er.2012-1030
[36] De Leo S, Lee SY, Braverman LE.  Hyperthyroidism[J]. Lancet, 2016, 388(10047): 906-918.   doi: 10.1016/S0140-6736(16)00278-6
[37]

Alvi AM, Azmat U, Shafiq W, et al. Efficacy of radioiodine therapy in patients with primary hyperthyroidism: an institutional review from Pakistan[J/OL]. Cureus, 2022, 14(5): e24992[2022-11-17]. https://www.cureus.com/articles/94830-efficacy-of-radioiodine-therapy-in-patients-with-primary-hyperthyroidism-an-institutional-review-from-pakistan#!. DOI: 10.7759/CUREUS.24992.
[38] Tarantini B, Ciuoli C, Di Cairano G, et al.  Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism[J]. J Endocrinol Invest, 2006, 29(7): 594-598.   doi: 10.1007/bf03344157
[39] Dunkelmann S, Wolf R, Koch A, et al.  Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay[J]. Eur J Nucl Med Mol Imaging, 2004, 31(10): 1428-1434.   doi: 10.1007/s00259-004-1519-8
[40] 刘娜, 刘雪辉.  131I治疗甲状腺自主高功能腺瘤诱发格雷夫斯病一例[J]. 中华核医学与分子影像杂志, 2019, 39(9): 548-549.   doi: 10.3760/cma.j.issn.2095-2848.2019.09.010
Liu N, Liu XH.  Graves disease after 131I therapy in a case of autonomously functioning thyroid adenoma[J]. Chin J Nucl Med Mol Imaging, 2019, 39(9): 548-549.   doi: 10.3760/cma.j.issn.2095-2848.2019.09.010
[41] 李冰, 刘虔, 丁小军, 等.  甲状腺结节的现代诊疗进展[J]. 现代生物医学进展, 2017, 17(19): 3783-3789.   doi: 10.13241/j.cnki.pmb.2017.19.047
Li B, Liu Q, Ding XJ, et al.  Progress in the diagnosis and treatment of thyroid nodules[J]. Prog Mod Biomed, 2017, 17(19): 3783-3789.   doi: 10.13241/j.cnki.pmb.2017.19.047
[42] Nygaard B, Faber J, Veje A, et al.  Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy[J]. Thyroid, 1999, 9(5): 477-481.   doi: 10.1089/thy.1999.9.477